# A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07750041/  
OnCo record `nct07750041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of bevacizumab (glioblastoma use) and regorafenib in colorectal cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.

## Summary

A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer is a phase 1/2, randomised interventional study registered as NCT07750041 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 260 participants, started 2026-08-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: SYS6090 (Fixed Dose Level A) + bevacizumab; SYS6090 (Fixed Dose Level B ) + bevacizumab; SYS6090 RP2D + bevacizumab +mFOLFOX6; SYS6090 RP2D + bevacizumab; Regorafenib; SYS6090 PR2D+ bevacizumab + FOLFOXIRI; bevacizumab + FOLFOXIRI. Conditions listed: Unresectable Advanced or Metastatic Colorectal Cancer. Primary outcome: Recommended Phase 2 Dose (RP2D), Safety and Tolerability; Objective Response Rate (ORR) assessed per RECIST v1.1; Progression-Free Survival (PFS) assessed per RECIST v1.1. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed unresectable advanced or metastatic colorectal cancer with pMMR/MSS status, assigned to corresponding cohorts as follows:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07750041
- Phase: 1/2
- Setting: A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Coloretal Cancer
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT07750041: https://clinicaltrials.gov/study/NCT07750041

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Regorafenib](https://onco.cc/drugs/regorafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07750041.json